Interesting article in the SMH today about a biotech considering moving to UK or US due to higher ratings.
Like Resmed, SRX gets the significant % of it's sales in the US (and will do so over the next few years - IMO) and at some point a duel listing may be beneficial.
PE ratios for biotechs in the US are far higher than Aus - now that would be interesting. Please :-)
ubs upgrade to buy, page-11
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $401.1K | 2.230M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 5285064 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 2965318 | 15 |
View Market Depth
| Last trade - 14.58pm 23/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |